Related Experiment Video
Updated: Jun 22, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Dose tolerability of chronically inhaled voriconazole solution in rodents
Justin A Tolman1, Nicole A Nelson, Stephanie Bosselmann
1The University of Texas at Austin College of Pharmacy, Austin, TX, United States.
Abstract:
Invasive pulmonary aspergillosis (IPA) is a fungal disease of the lung associated with high mortality rates in immunosuppressed patients despite treatment. Targeted drug delivery of aqueous voriconazole solutions has been shown in previous studies to produce high tissue and plasma drug concentrations as well as improved survival in a murine model of IPA. In the present study, rats were exposed to 20 min nebulizations of normal saline (control group) or aerosolized aqueous solutions of voriconazole at 15.625 mg (low dose group) or 31.25mg (high dose group). Peak voriconazole concentrations in rat lung tissue and plasma after 3 days of twice daily dosing in the high dose group were 0.85+/-0.63 microg/g wet lung weight and 0.58+/-0.30 microg/mL, with low dose group lung and plasma concentrations of 0.38+/-0.01 microg/g wet lung weight and 0.09+/-0.06 microg/mL, respectively. Trough plasma concentrations were low but demonstrated some drug accumulation over 21 days of inhaled voriconazole administered twice daily. Following multiple inhaled doses, statistically significant but clinically irrelevant abnormalities in laboratory values were observed. Histopathology also revealed an increase in the number of alveolar macrophages but without inflammation or ulceration of the airway, interstitial changes, or edema. Inhaled voriconazole was well tolerated in a rat model of drug inhalation.
Insights
Inhaled voriconazole demonstrates good tolerability and achieves therapeutic lung concentrations in a rat model. This targeted drug delivery offers a promising approach for treating invasive pulmonary aspergillosis (IPA).
Area of Science:
- Pharmacology
- Pulmonology
- Mycology
Background:
- Invasive pulmonary aspergillosis (IPA) presents a significant mortality risk in immunocompromised individuals.
- Current treatments for IPA have limitations, necessitating novel drug delivery strategies.
- Previous research indicated that targeted voriconazole delivery enhances drug concentrations and survival in a murine IPA model.
Purpose of the Study:
- To evaluate the tolerability and pharmacokinetic profile of inhaled voriconazole in a rat model.
- To assess the safety and efficacy of aerosolized voriconazole for potential IPA treatment.
Main Methods:
- Rats received nebulized normal saline (control), low-dose, or high-dose aerosolized voriconazole.
- Lung tissue and plasma voriconazole concentrations were measured after 3 and 21 days of twice-daily dosing.
- Laboratory values and histopathology were analyzed to assess safety and tolerability.
Main Results:
- Inhaled voriconazole achieved measurable concentrations in rat lung tissue and plasma.
- Low-level drug accumulation was observed over 21 days with twice-daily dosing.
- Statistically significant but clinically irrelevant laboratory abnormalities and increased alveolar macrophages were noted.
- Inhaled voriconazole was well-tolerated, with no observed airway inflammation or edema.
Conclusions:
- Inhaled voriconazole is well-tolerated in rats, suggesting a potentially safe delivery route.
- The study demonstrates the feasibility of achieving therapeutic voriconazole concentrations in the lungs via inhalation.
- Targeted inhaled voriconazole warrants further investigation as a treatment strategy for invasive pulmonary aspergillosis.
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimen: Multiple Oral Dosage
Dosage Regimens: Partial Pharmacokinetic Parameters
Dosage Interval and Administration Route: Determination Methods
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

